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Background: Acute phase hyperglycemia has been associated with increased mortality in patients with acute
myocardial infarction (AMI). However, the predictive value of glycemic excursion for adverse outcome in elderly AMI
patients is not clear. The aim of this study is to investigate the prognostic value of early in-hospital glycemic excursion
and hemoglobin A1c (HbA1c) for one-year major adverse cardiac event (MACE) in elderly patients with AMI.
Methods: We studied 186 elderly AMI patients, whose clinical data were collected and the Global Registry of Acute
Coronary Events (GRACE) risk score were calculated on admission. The fluctuations of blood glucose in patients were
measured by a continuous glucose monitoring system (CGMS) for 72 hours. Participants were grouped into tertiles of
mean amplitude of glycemic excursions (MAGE) and grouped into HbA1c levels (as ≥6.5% or <6.5%). The MACE of
patients, including new-onset myocardial infarction, acute heart failure and cardiac death, was documented during one
year follow-up. The relationship of MAGE and HbA1c to the incidence of MACE in elderly AMI patients was analyzed.
Results: In all participants, a higher MAGE level was associated with the higher GRACE score (r = 0.335, p < 0.001). The
rate of MACE by MAGE tertiles (>3.94 mmol/L, 2.55-3.94 mmol/L or <2.55 mmol/L) was 30.2% vs. 14.8% vs. 8.1%,
respectively (p = 0.004); by HbA1c category (≥6.5% vs. <6.5%) was 22.7% vs. 14.4%, respectively (p = 0.148). Elderly AMI
patients with a higher MAGE level had a significantly higher cardiac mortality. In multivariable analysis, high MAGE level
was significantly associated with incidence of MACE (HR 3.107, 95% CI 1.190-8.117, p = 0.021) even after adjusting for
GRACE risk score, but HbA1c was not.
Conclusions: The early in-hospital intraday glycemic excursion may be an important predictor of mortality and MACE
even stronger than HbA1c in elderly patients after AMI.Background
Increasing age is considered one of the most significant
risk factors for acute myocardial infarction (AMI) [1].
Ageing is also a risk factor that contributes to variance in
diabetes risk [2]. Dysglycemia is associated with poor out-
comes in AMI patients both with and without diabetes.
Chronic glucose dysregulation, as assessed by haemoglo-
bin A1c (HbA1c) levels, is a prognostic factor for mortality
in patients with AMI [3,4]. It is evident that admission
hyperglycemia is of independent prognostic value with re-
gard to future adverse cardiovascular events in patients
with AMI [5,6]. Recent studies have showed that glycemic* Correspondence: mishuhua@hotmail.com
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reproduction in any medium, provided the orexcursion might play an important role in the pathogen-
esis of atherosclerosis and may be an independent risk fac-
tor for cardiovascular complications in diabetics [7,8].
However, it still remains unclear whether acute glycemic
excursion has the important prognostic significance in
elderly AMI patients. The purpose of the current study is
therefore to investigate the independent prognostic value
of glycemic excursion determined by a continuous glucose




Consecutive patients admitted to the cardiology depart-
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60 years old; (ii) confirmed admission diagnosis of AMI
including ST segment elevated myocardial infarction
(STEMI) and non-ST segment elevated myocardial infarc-
tion (NSTEMI); (iii) admission glucose < 16.7 mmol/L,
and without diabetic ketosis or nonketotic hyperosmolar
coma. AMI was defined as acute if the time elapsed be-
tween the first symptom and admission was 72 h or less.
To enable long-term follow-up and repeated visits to our
outpatient clinic, only patients under the age of 80 and liv-
ing within the hospital’s catchment area were eligible. The
exclusion criteria were severe non-cardiac disease with
expected survival of less than one year and unwillingness
to participate. A patient could only be included once.
Data, including information on previous clinical history,
cardiovascular risk factors and medication, were collected
in hospital. Type 2 diabetes mellitus (T2DM) was diag-
nosed according to the American Diabetes Association
criteria or the use of insulin or glucose-lowering medica-
tion. The estimated glomerular filtration rate (eGFR) value
was calculated by MDRD equation [9]. The Global Regis-
try of Acute Coronary Events (GRACE) risk score were
calculated as admission [10], which is recommended by
the National Institute for Health and Clinical Excellence
(NICE) to assess risk in patients with ACS. Patients were
categorized according to tertiles of the mean amplitude of
glycemic excursions (MAGE) level (<2.55 mmol/L, 2.55-
3.94 mmol/L and >3.94 mmol/L), and according to HbA1c
(<6.5% and ≥6.5%) [11]. The study protocol was approved
beforehand by the Medical Ethics Committee of Beijing
An Zhen Hospital of Capital Medical University and
the procedures followed were in accordance with the insti-
tutional guidelines. The study complied with the declar-
ation of Helsinki and informed consent was obtained from
all patients.
Continuous glucose monitoring
All patients were equipped with CGMS (Medtronic Mini-
Med, USA), and were monitored for 72 consecutive hours
after admission. A CGMS sensor was inserted into the
subcutaneous abdominal fat tissue, calibrated according to
the standard Medtronic MiniMed operating guidelines.
During CGMS monitoring, patients checked their blood
glucose level with a self-monitoring of blood glucose
(SMBG) device (Medisafe Mini, Terumo, Japan) at least 4
times per day. Then, they entered the SMBG data and
time of each meal into the CGMS. After monitoring for
72 hours, the recorded data were downloaded into a per-
sonal computer for analysis of the glucose profile and gly-
cemic excursion parameters with MiniMed Solutions
software. After downloading the recorded data, the inter-
mediate 48 hours of recording was analyzed to avoid bias
due to insertion and removal of the CGMS or insufficient
stability of the monitoring system, and MAGE wascaculated from the first 24 hours of them. Since measur-
able range of glucose by CGMS was mechanically limited
from 2.2 to 22.2 mmol/L, the case showing the data out of
this range was excluded from the study. The MAGE was
calculated by measuring the arithmetic mean of the differ-
ences between consecutive peaks and nadirs, provided
that the differences are greater than one standard devi-
ation (SD) of the mean glucose value [12]. Patients would
maintain anti-hyperglycemic therapy as usual and be
avoided glucose infusion during CGMS monitoring
period. Otherwise, the patient would be excluded from
the study.
Biochemical investigations
Blood samples were collected after overnight fasting and
stored at −70C prior to analysis. Serum creatinine, total
cholesterol (TC) and triglyceride (TG) levels were mea-
sured by automatic biochemical analyzer (Hitachi 747,
Tokyo, Japan). Serum concentration of hemoglobin A1c
(HbA1c) was determined by high-performance liquid
chromatographic method using automatic HbA1c
analyzer (Tosoh HLC-723 G7, Japan).
Follow-up
Patients were followed up prospectively for about 1 year.
During follow-up period, incidences of major adverse
cardiac event (MACE) were registered, including new-
onset myocardial infarction, acute heart failure and car-
diac death. All MACE data were adjudicated by an
experienced cardiovascular physician blinded to clinical
details and outcomes.
Statistical analysis
All statistical analyses were performed by using SPSS for
Windows 13.0 (SPSS Inc, Chicago, IL, USA). Data are
presented as frequencies and percentages for categorical
variables and mean ± SD for continuous variables, unless
otherwise indicated. Differences between two groups
were assessed by using the Chi-square and unpaired
t-tests. Correlation between continuous variables was
determined by Spearman correlation coefficients. MAGE
was included as a continuous and as a categorized
(<2.55 mmol/L, 2.55-3.94 mmol/L and >3.94 mmol/L)
variable. HbA1c level was also included as a continuous
and categorized (<6.5% and ≥6.5%) variable. Kaplan-
Meier survival curve analysis was used to represent the
proportional risk of MACE for the MAGE and HbA1c
values, and the log-rank test was performed to assess
differences between high MAGE level and low MAGE
level, and high HbA1c level and low HbA1c level. Cox
proportional-hazards regression models were used to
estimate hazard ratios of clinical variables with regard
to MACE. A value of p < 0.05 was considered statistically
significant.
Table 1 Baseline characteristics in AMI patients according
to MAGE
MAGE (mmol/L) < 2.55 2.55-3.94 > 3.94
n 62 61 63
Age (years) 65.5 ± 5.2 67.1 ± 5.0 68.4 ± 6.4 *
Males 43 (69.4) 34 (55.7) 39 (61.9)
Risk factors
Diabetes 22 (35.5) 32 (52.5) 47 (74.6) *#
Previous CAD 14 (22.6) 15 (24.6) 29 (46.0) *#
Smoking 22 (35.5) 18 (29.5) 34 (54.0) *#
BMI (kg/m2) 25.9 ± 2.4 26.5 ± 2.7 26.8 ± 3.3
Systolic BP (mmHg) 125 ± 18 127 ± 18 130 ± 23
Diastolic BP (mmHg) 75 ± 10 77 ± 9 78 ± 11
Heart rate (bpm) 68 ± 12 73 ± 12 * 72 ± 11 *
LVEF (%) 58.2 ± 10.5 57.2 ± 13.4 51.4 ± 11.1 *#
eGFR (ml/min/1.73 m2) 76.2 ± 30.3 64.2 ± 26.5 * 62.5 ± 20.8 *
TC (mmol/L) 4.46 ± 0.99 4.55 ± 1.02 4.62 ± 1.15
TG (mmol/L) 2.13 ± 1.04 1.96 ± 0.99 2.25 ± 1.78
FBG (mmol/L) 6.53 ± 1.96 7.41 ± 2.29 * 8.31 ± 2.98 *
HbA1c (%) 5.8 ± 0.9 6.4 ± 1.2 * 7.1 ± 1.2 *
Medications
Aspirin 58 (93.5) 55 (90.1) 60 (95.2)
Beta-blocker 24 (38.7) 24 (39.3) 30 (47.6)
Oral anti-hyperglycemic 19 (30.6) 22 (36.1) 26 (41.3)
Insulin 8 (12.9) 22 (36.1) * 33 (52.4) *
ACEI 25 (40.3) 30 (49.2) 32 (50.8)
Statin 48 (77.4) 47 (77.0) 51 (80.9)
Diuretic 9 (14.5) 11 (18.0) 17 (27.0)
Type of AMI
STEMI 37 (59.7) 49 (80.3) * 48 (76.2) *
Non-STEMI 25 (40.3) 12 (19.7) * 15 (23.8) *
GRACE Score 128 ± 29 144 ± 29 * 155 ± 39 *
Abbreviations: MAGE, the mean amplitude of glycemic excursions; CAD,
coronary artery disease; BMI, body mass index; BP, blood pressure; LVEF, left
ventricular ejection fraction; eGFR, estimated glomerular filtration rate; TC,
total cholesterol; TG, triglyceride; FBG, fasting blood glucose; HbA1c,
hemoglobin A1c; ACEI, angiotensin converting enzyme inhibitor; AMI, acute
myocardial infarction; STEMI, ST segment elevated myocardial infarction;
GRACE, the global registry of acute coronary events. * p < 0.05 vs. MAGE <
2.55 mmol/L; # p < 0.05 vs. MAGE 2.55-3.94 mmol/L. Data are mean ± SD and
number (%).
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Baseline characteristics
During the study period, 200 elderly AMI patients were
enrolled. 186 patients with complete data were included
in the final analysis (8 patients were removed from study
for severe dysglycemia during CGMS monitoring period;
6 patients were excluded from study for incomplete
follow-up data). Mean age was 67.0 ± 5.7 years, 60.4%
were male and 54.3% had diabetes. Participants were
treated conservatively (9.1%), with PCI (80.1%) or with
CABG (10.8%). HbA1c was < 6.5% in 111 (59.7%), ≥ 6.5%
in 75 (40.3%). The GRACE risk score ranged from 78 to
235 with a mean of 148 ± 36. Baseline characteristics of
patient groups based on MAGE and HbA1c are shown
in Table 1 and 2, respectively. The correlation of GRACE
score with MAGE or HbA1c was significant (Spearman
r = 0.335, p < 0.001; r = 0.188, p = 0.010).
Incidences of MACE
At the end of 1-year follow-up, 10 patients had died
(5.4%) for cardiac causes, 13 patients had new-onset
myocardial infarction (7.0%), and 10 patients had acute
heart failure (5.4%). As expected, elderly AMI patients
with MAGE level >3.94 mmol/L had significantly higher
incidence of MACE compared with elderly AMI patients
with MAGE level from 2.55 mmol/L to 3.94 mmol/L, or
< 2.55 mmol/L (30.2% vs. 14.8% vs. 8.1%, p = 0.004).
No significant rates of adverse cardiovascular events
were observed between patients with HbA1c level ≥6.5%
and patients with HbA1c level < 6.5% (22.7% vs. 14.4%,
p = 0.148). Elderly AMI patients with a higher MAGE
level had a significantly higher cardiac mortality com-
pared with elderly AMI patients with lower MAGE
levels (11.1% vs. 1.6% vs. 3.2%, p = 0.043) (Figure 1). No
significant differences in rates of adverse cardiovascular
events were observed between elderly AMI patients
with high HbA1c level and patients with low HbA1c level
(Figure 2). Kaplan-Meier survival curves for patient
groups by MAGE are shown in Figure 3; those for
HbA1c in Figure 4.
Multivariable analysis
To investigate the associations between MAGE, HbA1c
level and incidences of MACE with respect to baseline
characteristics, we used multivariable analysis. Include
variables were: age, gender, and all variables that were
significantly different between MAGE or HbA1c categor-
ies [current smoking, diabetes, previous coronary artery
disease (CAD), heart rate, eGFR, anti-hyperglycemic
agents, fasting blood glucose, the STEMI presentation,
left ventricular ejection fraction (LVEF, categorized into
<50% = 1 and ≥50% = 0) and diuretics]. The independent
predictors of MACE were: age (HR 1.624, 95% CI 1.036-
2.548, p = 0.035), previous CAD (HR 2.907, 95% CI1.227-6.896, p =0.015), LVEF (HR 2.611, 95% CI 1.107-
6.135, p = 0.028) and MAGE (HR 3.131, 95% CI 1.422-
6.710, p = 0.014). HbA1c level was not significantly asso-
ciated with MACE (HR 1.522, 95% CI 0.841-2.757,
p = 0.165). After adjustment for the GRACE score,
MAGE was found to be also associated with incidences
of MACE (HR 3.107, 95% CI 1.190-8.117, p = 0.021),
but HbA1c was not (HR 1.438, 95% CI 0.619-5.464,
p = 0.273).
Table 2 Baseline characteristics in AMI patients according
to HbA1c level
HbA1c (%) < 6.5 ≥ 6.5 P
n 111 75
Age (years) 66.0 ± 5.1 68.6 ± 6.2 0.002
Males 67 (60.4) 49 (65.3) 0.492
Risk factors
Diabetes 49 (44.1) 52 (69.3) 0.001
Previous CAD 30 (27.0) 28 (37.3) 0.137
Smoking 41 (36.9) 33 (44.0) 0.334
BMI (kg/m2) 26.3 ± 2.8 26.5 ± 3.0 0.556
SBP (mmHg) 126 ± 18 128 ± 21 0.435
DBP (mmHg) 76 ± 10 77 ± 13 0.720
HR (bpm) 70 ± 11 72 ± 13 0.234
LVEF (%) 57.8 ± 11.6 53.2 ± 11.9 0.010
eGFR (ml/min/1.73 m2) 70.6 ± 31.8 63.2 ± 25.7 0.061
TC (mmol/L) 4.45 ± 0.97 4.67 ± 1.15 0.167
TG (mmol/L) 1.96 ± 1.00 2.34 ± 1.68 0.056
FBG (mmol/L) 6.58 ± 1.73 9.12 ± 2.63 < 0.001
MAGE (mmol/L) 2.64 ± 1.23 4.15 ± 1.28 < 0.001
Medications
Aspirin 101 (91.0) 72 (96.0) 0.189
Beta-blocker 46 (41.4) 32 (42.7) 0.868
Oral anti-hyperglycemic 24 (21.6) 43 (57.3) < 0.001
Insulin 17 (15.3) 46 (61.3) < 0.001
ACEI 51 (45.9) 36 (48.0) 0.783
Statin 85 (76.6) 61 (81.3) 0.439
Diuretic 13 (11.7) 24 (32.0) 0.001
Type of AMI
STEMI 74 (66.7) 60 (80.0) 0.047
Non-STEMI 37 (33.3) 15 (20.0) 0.047
GRACE Score 137 ± 32 151 ± 36 0.005
Abbreviations: HbA1c, hemoglobin A1c; CAD, coronary artery disease; BMI, body
mass index; BP, blood pressure; LVEF, left ventricular ejection fraction; eGFR,
estimated glomerular filtration rate; TC, total cholesterol; TG, triglyceride; FBG,
fasting blood glucose; MAGE, the mean amplitude of glycemic excursions;
ACEI, angiotensin converting enzyme inhibitor; AMI, acute myocardial
infarction; STEMI, ST segment elevated myocardial infarction; GRACE, the
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Figure 1 Incidence of MACE after 1-year follow-up in relation
to MAGE levels. Elderly AMI patients with a higher MAGE level had
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Figure 2 Incidence of MACE after 1-year follow-up in relation
to HbA1c levels. There are no significant differences of adverse
cardiovascular events rates between different HbA1c level groups
(all p > 0.05).
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Hyperglycemia on admission is common in patients with
AMI, and it is a powerful predictor of survival and
increased risk of MACE in patients both with and with-
out T2DM [3,5,6]. HbA1c is a convenient marker of
long-term glycometabolic status. Elevated HbA1c is asso-
ciated with increased cardiovascular risk in patients.
However, patients with similar mean glucose or HbA1c
levels can have markedly different glycemic excursions
[13]. Acute glucose fluctuations seem to have moredeleterious effects than sustained hyperglycemia in the
development of cardiovascular complications as glucose
both upward and downward changes activate the oxida-
tive stress [14,15]. We investigated the association be-
tween glycemic excursion, HbA1c and one-year MACE
in elderly patients with AMI. Our study demonstrated
that elevated MAGE was a strong and independent pre-
dictor of increased risk of MACE in elderly patients with
AMI, but HbA1c was not.
There were major differences in baseline characteris-
tics according to MAGE or HbA1c level. Patients with
higher MAGE or HbA1c level had more cardiovascular
risk factors, such as older age, diabetes, heart failure or
renal insufficiency. There was also a clear correlation be-
tween GRACE risk scores and MAGE or HbA1c. The
Figure 3 Kaplan-Meier event-free survival curves for freedom from MACE in three patient groups by MAGE levels. The event-free
survival rate was significantly lower in the high MAGE level group (log-rank test, p = 0.003).
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cometabolic disorders may be associated with poorer
outcomes.
More and more evidences show that glycemic variabil-
ity may be an important parameter used to resolveFigure 4 Kaplan-Meier event-free survival curves for freedom from M
lower event-free survival rate in high HbA1c level patients (log-rank test, p =potential clinical problems in diabetes. It is reported that
postchallenge glucose excursion is independently related
to carotid intima-media thickness and may contribute to
the development of atherosclerosis in individuals with
T2DM independent of other risk factors [7,16]. In ourACE in two patient groups by HbA1c levels. There is not significant
0.107).
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important contributing factor in the severity of coronary
artery disease, which is independent of the average level of
blood glucose [8]. The Verona Diabetes study reported
that fasting glycemic variability is an independent pre-
dictor of mortality in T2DM patients [17]. Some studies
concluded that glycemic excursion was a significant pre-
dictor of mortality in critically ill patients independently
from mean glucose level and severity of illness [18,19]. In
the present study, patients with a higher MAGE level have
higher GRACE risk scores. After 1-year follow-up, a sig-
nificantly higher incidence of MACE and cardiac mortality
were found in those patients. The results indicate that
high glucose fluctuations may be associated with the risk
of future adverse cardiovascular events in patients with
AMI. Multivariable analysis disclosed that in the elderly
AMI population, MAGE was an independent predictor of
MACE, even after adjusting for GRACE risk score, but
HbA1c was not.
Acute hyperglycaemia is a common acute adrenergic
signal of stress and is present in myocardial infarction,
whereas increased catecholamine levels result in decreased
insulin secretion and increased insulin resistance [20]. Al-
though stress-induced hyperglycaemia can partly explain
the relation between admission glycemic variability and
outcomes, glycemic excursion itself can also be harmful.
Ceriello et al. reported that intermittent hyperglycaemia
induced a higher degree of apoptosis in endothelial cells
than chronic hyperglycaemia [14]. Quagliaro et al. showed
that the apoptosis of endothelial cells exposed to intermit-
tent high glucose may be related to a reactive oxygen spe-
cies (ROS) overproduction, through protein kinase C
(PKC)-dependent activation of nicotinamide adenine di-
nucleotide phosphate (NADPH)-oxidase [21]. Glycemic
excursion may also be an important mediator in inflam-
matory responses. In vitro studies indicate that glucose
fluctuations can activate nuclear factor-κB and PKC path-
way, leading to a greater expression of the adhesion mole-
cules and excess formation of advanced glycation end-
products than stable high glucose [22]. Moreover, severe
glycemic disorders may adversely affect sympathetic dys-
function which is associated with mortality and morbidity
of cardiovascular disease [23].
Although both HbA1c and glycemic excursion may be
associated with adverse prognosis, our study show that
increased MAGE is more important. In our analysis, the
less clear association between HbA1c and MACE could
be due to a limited number of patients with a relatively
short follow-up in present study. Increased HbA1c repre-
sents long-term glucose regulation, whereas elevated gly-
cemic excursion is not only a symptom of glucose
dysregulation, but also of stress and general poor health.
Carmen Wong et al. found cortisol level is correlated
with acute hyperglycaemia in patients with AMI [24].There is a clear association to be found between HbA1c
and long-term outcome in AMI patients after 3.3 years
follow-up [25]. These differences may relate to length of
follow-up. HbA1c may have limited predictive power for
short-term prognosis in patients with AMI, but its asso-
ciation with long-term prognosis may be stronger.
There is still an extensive debate about glycemic ex-
cursion as a risk factor for cardiovascular complications
independent of HbA1c [26,27]. Siegelaar et al. performed
reanalysis of the data of the HEART2D, which shows
that targeting post-prandial glucose decreased intraday
glycemic excursion would not be beneficial in reducing
adverse cardiovascular events in AMI patients [28].
However, the HEART2D was not designed to determine
the impact of glycemic excursion on the risk of MACE,
and the MAGE and SD levels were not found significantly
different between two contrasting groups in the study. In
addition, the method of calculating glycemic excursion
from self-measured blood glucose profiles may be not very
accurate. Overall, more well-designed studies are needed
to investigate whether glycemic excursion will play an im-
portant role in the prognosis of AMI.Study limitations
The sample size was relatively small, so that comparisons
of some subgroups might lack power to detect significant
differences for selected variables. For lack of microvascular
complications data, we didn’t include those risk factors in
analysis. Although we had maintained the patients’ anti-
hyperglycemic therapy as usual and avoided glucose infu-
sion during CGMS monitoring period, some factors, such
as different diets, physical and emotional stress etc., which
may affect glucose fluctuations couldn’t be all prevented.
In addition, tests to detect diabetes were not routinely
done, so some cases of diabetes may have been missed.
However, if the observed relation between glycemic excur-
sion and MACE was due to undiagnosed diabetes, one
would have expected a more distinct association between
HbA1c and outcomes.Conclusions
In elderly patients, early in-hospital MAGE may be an
important predictor of mortality and MACE after AMI
even stronger than HbA1c. The results of this study fur-
ther support the view that glycemic excursion should be
one of the targets of treatment for the glycemic disor-
ders encountered in AMI patients. Further studies are
needed to determine if pharmacologic therapy aimed at
controlling glucose excursion in AMI would be benefi-
cial in prognosis of this high-risk patient population.
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